Recombinant IL2RA (Daclizumab Biosimilar) anticorps

N° du produit ABIN7487796

Détail du produit anti-IL2RA (Daclizumab Biosimilar) anticorps

Antigène: IL2RA (Daclizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp IL2RA (Daclizumab Biosimilar) est non-conjugé

Application: ELISA

Fonction: Daclizumab Biosimilar - Anti-IL2RA mAb

Attributs du produit: Antibody Type: IgG1-kappa

Classe de qualité: Research Grade

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur IL2RA (Daclizumab Biosimilar)

Antigène: IL2RA (Daclizumab Biosimilar)

Abstract: IL2RA (Daclizumab Biosimilar) Produits

Synonymes: anticorps CD25, anticorps IDDM10, anticorps IL2R, anticorps TCGFR, anticorps interleukin 2 receptor subunit alpha, anticorps IL2RA

Classe de substances: Biosimilar

Sujet: BIIB019,DAC HYP
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

Numéro CAS: 152923-56-3